LogoPressRelease.jpg
Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
December 14, 2018 16:05 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its...
LogoPressRelease.jpg
Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock
December 12, 2018 01:01 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an...
LogoPressRelease.jpg
Fluidigm Announces Commencement of Public Offering of Common Stock
December 11, 2018 16:01 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to...
LogoPressRelease.jpg
Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
November 12, 2018 16:05 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
LogoPressRelease.jpg
Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
November 08, 2018 08:30 ET | Fluidigm Corporation
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation...
LogoPressRelease.jpg
Fluidigm Recognized as a Company to Watch in 2019
November 07, 2018 16:11 ET | Fluidigm Corporation
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm...
LogoPressRelease.jpg
Fluidigm Announces Third Quarter 2018 Financial Results
November 01, 2018 16:05 ET | Fluidigm Corporation
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018...
LogoPressRelease.jpg
Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
October 25, 2018 08:30 ET | Fluidigm Corporation
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) --...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
October 01, 2018 16:15 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...
LogoPressRelease.jpg
Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD
September 07, 2018 07:30 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to...